Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome

Lipids in Health and Disease

Shui-ping Zhao¹  Dan-yan Xu¹  Jian-qing Du¹  Xuan Zhao¹ 

[1] Department of Cardiology & Internal Medicine, Second Xiangya Hospital, Central South University, 139 Middle Ren min Road, Changsha, 410011, PR China

关键词: Acute coronary syndrome;    Fatty acid synthase;    Soluble epoxide hydrolase inhibitor;   

Others  :  1160104
DOI  :  10.1186/1476-511X-12-3

 received in 2012-11-15, accepted in 2013-01-04,  发布年份 2013

【 摘 要 】

Background

Researches have shown that soluble epoxide hydrolase inhibitors (sEHi) can protect against the development of atherosclerosis. Simultaneously, emerging evidences have implicated the association between fatty acid synthase (FAS) and acute coronary syndrome (ACS). We tested the hypothesis that sEHi could reduce the occurrence of ACS by regulating FAS.

Methods

Hospitalized ACS patients were selected as the ACS group (n = 65) while healthy normal subjects as the control group (n = 65). The blood levels of lipoproteins, fasting glucose, myocardial enzyme and high-sensitivity C-reactive protein (hs-CRP) were measured within 24 hours after admission. The peripheral blood mononuclear cells (PBMCs) were isolated and cultured. Trans-4-[4-(3-Adamantan-1-ylureido)cyclohexyloxy] benzoic acid (t-AUCB), a kind of sEHi, was then added to cells in various concentrations (0, 10, 50, 100 μmol/L). The expression of FAS, interleukin-6 (IL-6) mRNA and protein was detected by real-time PCR or Western blot, respectively.

Results

(1) Compared with the control group, the serum concentration of hs-CRP in the ACS group was increased (P<0.05). The expression of FAS, IL-6 mRNA and protein were significantly increased in PBMCs from the ACS group (all P<0.05). Moreover, the levels of FAS and IL-6 mRNA were positively correlated with the serum concentration of hs-CRP (r = 0.685, P<0.01; r = 0.715, P<0.01) respectively. (2) The expression of FAS, IL-6 mRNA and protein in PBMCs from the ACS group were dose-dependently inhibited by sEHi (all P<0.05).

Conclusions

sEH inhibition regulated FAS and inhibited inflammation in cultured PBMCs from ACS patients, a mechanism that might prevent rupture of atherosclerotic lesions and protect against development of ACS.

【 授权许可】

   
2013 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Sato Y, Hatakeyama K, Marutsuka K, Asada Y: Incidence of asymptomatic coronary thrombosis and plaque disruption: comparison of non-cardiac and cardiac deaths among autopsy cases. Thromb Res 2009, 124(1):19-23.
• [2]Fishbein MC: The vulnerable and unstable atherosclerotic plaque. Cardiovasc Pathol 2010, 19(1):6-11.
• [3]Marshall K: Acute coronary syndrome: diagnosis, risk assessment and management. Nurs Stand 2011, 25(23):47-57. quiz 58, 60
• [4]Hong YJ, Jeong MH, Choi YH, Song JA, Kim DH, Lee KH, Yamanaka F, Lee MG, Park KH, Sim DS, et al.: Relation between anemia and vulnerable coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis. J Korean Med Sci 2012, 27(4):370-376.
• [5]Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R: Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010, 30(7):1282-1292.
• [6]Schneider JG, Yang Z, Chakravarthy MV, Lodhi IJ, Wei X, Turk J, Semenkovich CF: Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis. J Biol Chem 2010, 285(30):23398-23409.
• [7]Felton CV, Crook D, Davies MJ, Oliver MF: Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997, 17(7):1337-1345.
• [8]Wu X, Zayzafoon M, Zhang X, Hameed O: Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: a comparison with AMACR. Am J Clin Pathol 2011, 136(2):239-246.
• [9]Ecker J, Liebisch G, Englmaier M, Grandl M, Robenek H, Schmitz G: Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. Proc Natl Acad Sci USA 2010, 107(17):7817-7822.
• [10]Kaski JC: Molecular imaging of inflammation for detection of vulnerable atheromatous plaques. Eur Heart J 2012, 33(15):1857-–1860.
• [11]Anogeianaki A, Angelucci D, Cianchetti E, D'Alessandro M, Maccauro G, Saggini A, Salini V, Caraffa A, Tete S, Conti F, et al.: Atherosclerosis: a classic inflammatory disease. Int J Immunopathol Pharmacol 2011, 24(4):817-825.
• [12]Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G: Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012, 18(28):4266-4288.
• [13]Berndt J, Kovacs P, Ruschke K, Kloting N, Fasshauer M, Schon MR, Korner A, Stumvoll M, Bluher M: Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes. Diabetologia 2007, 50(7):1472-1480.
• [14]Rae C, Graham A: Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages. Diabetes Obes Metab 2008, 10(12):1271-1274.
• [15]Mei M, Zhao L, Li Q, Chen Y, Huang A, Varghese Z, Moorhead JF, Zhang S, Powis SH, Ruan XZ: Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice. Lipids Health Dis 2011, 10:110. BioMed Central Full Text
• [16]Larsen BT, Campbell WB, Gutterman DD: Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci 2007, 28(1):32-38.
• [17]Zhao TT, Wasti B, Xu DY, Shen L, Du JQ, Zhao SP: Soluble epoxide hydrolase and ischemic cardiomyopathy. Int J Cardiol 2012, 155(2):181-187.
• [18]Imig JD, Hammock BD: Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009, 8(10):794-805.
• [19]Ni GH, Chen JF, Chen XP, Yang TL: Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases. Pharmazie 2011, 66(3):153-157.
• [20]Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I: Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45(4):759-765.
• [21]Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD: The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007, 50(3):225-237.
• [22]Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD: Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005, 102(28):9772-9777.
• [23]Norwood S, Liao J, Hammock BD, Yang GY: Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res 2010, 2(4):447-457.
• [24]Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH: Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol 2008, 52(4):314-323.
• [25]Achar SA, Kundu S, Norcross WA: Diagnosis of acute coronary syndrome. Am Fam Physician 2005, 72(1):119-126.
• [26]Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS: C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance. Diabetes Care 2003, 26(8):2323-2328.
• [27]Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD: Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007, 50(16):3825-3840.
• [28]Mulvihill NT, Foley JB: Inflammation in acute coronary syndromes. Heart 2002, 87(3):201-204.
• [29]Tousoulis D, Hatzis G, Papageorgiou N, Androulakis E, Bouras G, Giolis A, Bakogiannis C, Siasos G, Latsios G, Antoniades C, et al.: Assessment of acute coronary syndromes: focus on novel biomarkers. Curr Med Chem 2012, 19(16):2572-2587.
• [30]Shantsila E, Lip GYH: Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2009, 29(10):1433-1438.
• [31]Futterman LG, Lemberg L: High-sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events. Am J Crit Care 2002, 11(5):482-486.
• [32]Calabro P, Golia E, Yeh ET: CRP and the risk of atherosclerotic events. Semin Immunopathol 2009, 31(1):79-94.
• [33]Munk PS, Larsen AI: [Inflammation and C-reactive protein in cardiovascular disease]. Tidsskr Nor Laegeforen 2009, 129(12):1221-1224.
• [34]Forte L, Cimmino G, Loffredo F, De Palma R, Abbate G, Calabro P, Ingrosso D, Galletti P, Carangio C, Casillo B, et al.: C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. Int J Cardiol 2011, 152(1):7-12.
• [35]Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the aggrastat-to-zocor trial. Circulation 2006, 114(4):281-288.
• [36]Holvoet P: Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008, 70(3):193-219.
• [37]Tavora FR, Ripple M, Li L, Burke AP: Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord 2009, 9:27. BioMed Central Full Text
• [38]Shibata N, Glass CK: Regulation of macrophage function in inflammation and atherosclerosis. J Lipid Res 2009, 50(Suppl):S277-281.
• [39]Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005, 3(1):63-68.
• [40]Vanella L, Kim DH, Sodhi K, Barbagallo I, Burgess AP, Falck JR, Schwartzman ML, Abraham NG: Crosstalk between EET and HO-1 downregulates Bach1 and adipogenic marker expression in mesenchymal stem cell derived adipocytes. Prostaglandins Other Lipid Mediat 2011, 96(1–4):54-62.
• [41]Habtezion A, Kwan R, Yang AL, Morgan ME, Akhtar E, Wanaski SP, Collins SD, Butcher EC, Kamal A, Omary MB: Heme oxygenase-1 is induced in peripheral blood mononuclear cells of patients with acute pancreatitis: a potential therapeutic target. Am J Physiol Gastrointest Liver Physiol 2011, 300(1):G12-20.
• [42]Ronnett GV, Kim EK, Landree LE, Tu Y: Fatty acid metabolism as a target for obesity treatment. Physiol Behav 2005, 85(1):25-35.
• [43]Zhang LN, Vincelette J, Cheng Y, Mehra U, Chen D, Anandan SK, Gless R, Webb HK, Wang YX: Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009, 29(9):1265-1270.
• [44]Machnicki M: [Regulation of interleukin 6 (IL-6) and TNF-alpha through lactoferrin in mice]. Postepy Hig Med Dosw 1995, 49(1):53-57.